跳至主要内容
临床试验/NL-OMON52527
NL-OMON52527尚未招募不适用

TIming of start of systemIc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preference cohort. - TIMEPA

Academisch Medisch Centrum0 个研究点目标入组 184 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
184

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • 1. Signed, written Institutional Review Board/Ethics Committee-approved
  • Informed Consent Form (ICF).
  • 2. Patients with histologically/cytological confirmed diagnosis of metastatic
  • pancreatic ductal adenocarcinoma.
  • 3. Measurable disease on computed tomography (CT) scan per RECIST version 1.1
  • 4. Eastern Cooperative Oncology Group Performance Status of 0-1.
  • 5. Life expectancy >= 3 months.
  • 6. Age >= 18 years.
  • 7. No symptoms related to advanced disease.

排除标准

  • 1. Known central nervous system involvement or brain metastases.
  • 2. New York Heart Association Class III or IV cardiac disease or myocardial
  • infarction within the past 12 months.
  • 3. Any other disease, active, uncontrolled bacterial, viral or fungal infection
  • requiring systemic therapy, metabolic dysfunction, physical examination finding
  • or clinical laboratory finding that leads to reasonable suspicion of a disease
  • or condition that contraindicates the use of an investigational drug, that may
  • affect the interpretation of the results, or that may render the subject at
  • high risk for treatment complications.
  • 4. Inability to comply with study and follow-up procedures as judged by the
  • Investigator.
  • 5. Women currently pregnant or breastfeeding.

研究者

相似试验